Table 1 Baseline characteristics of the study subjects
Budesonide/Salbutam ol group (n = 45) | Budesonide/Formoterol group (n = 45) | |
|---|---|---|
Age, years | 8.6 ± 2.3 | 8.9 ± 2.13 |
Sex- male/female, n | 33/12 | 30/15 |
Weight, kg | 23.3 ± 6.3 | 25 ± 8.2 |
Height, cm | 127.2 ± 14.2 | 129 ± 13.5 |
Duration of symptoms, days | 6.0 ± 3.6 | 6.1 ± 4.1 |
Cough | 44 (98%) | 44 (98%) |
Breathlessness | 45 (100%) | 41 (91%) |
Night symptoms | 27 (60%) | 33 (73%) |
Wheeze | 24 (53%) | 23 (51%) |
Frequency of exacerbations | ||
per year [median(IQR)] | ||
Type of asthma | ||
1. Mild intermittent | 19 (42%) | 18 (40%) |
2. Mild persistent | 15 (33%) | 15 (33%) |
3. Moderate persistent | 10 (22%) | 12 (27%) |
4. Severe persistent | 1 (2%) | 0 (0%) |
MPIS | 7.3 ± 1.2 | 7.2 ± 1.0 |
FEV1 (% predicted) | 58.2 ± 18.1; N = 43 | 55.9 ± 14.8 |
PEFR (% predicted) | 55.5 ± 21.5; N = 43 | 58.6 ± 16.3 |
FVC (% predicted) | 61.5 ± 28.3; N = 43 | 53.8 ± 20.8 |
FEF50 (% predicted) | 65.9 ± 37.6; N = 43 | 70.6 ± 23.7 |
FEV1/FVC (% predicted) | 84.9 ± 21.9; N = 43 | 91.4 ± 14.5 |